News
XOMA
26.00
-1.07%
-0.28
Weekly Report: what happened at XOMA last week (1223-1227)?
Weekly Report · 12/30/2024 11:38
Weekly Report: what happened at XOMA last week (1216-1220)?
Weekly Report · 12/23/2024 11:46
XOMA Royalty Corporation Announces Cash Dividends for Series A and Series B Preferred Stock
Barchart · 12/19/2024 16:52
Press Release: XOMA Royalty Declares Quarterly Preferred Stock Dividends
Dow Jones · 12/19/2024 12:30
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Barchart · 12/19/2024 06:30
Weekly Report: what happened at XOMA last week (1209-1213)?
Weekly Report · 12/16/2024 11:47
Xoma’s Strategic Partnerships and Promising Pipeline Drive Buy Rating
TipRanks · 12/13/2024 16:55
HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $123 Price Target
Benzinga · 12/13/2024 16:51
Weekly Report: what happened at XOMA last week (1202-1206)?
Weekly Report · 12/09/2024 11:45
A Glimpse Into The Expert Outlook On XOMA Royalty Through 4 Analysts
Benzinga · 12/03/2024 21:01
XOMA Price Target Raised to $123.00/Share From $117.00 by HC Wainwright & Co.
Dow Jones · 12/03/2024 12:45
XOMA Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/03/2024 12:45
HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $123
Benzinga · 12/03/2024 12:36
Xoma (XOMA) Receives a Hold from TD Cowen
TipRanks · 12/02/2024 20:25
XOMA Royalty Acquires Pulmokine, Adding Seralutinib as its Seventh Phase 3 Royalty Asset
Barchart · 12/02/2024 16:48
Strategic Acquisitions and Growth Potential Bolster Xoma’s Buy Rating
TipRanks · 12/02/2024 16:35
HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Raises Price Target to $123
Benzinga · 12/02/2024 16:32
Xoma price target raised to $123 from $117 at H.C. Wainwright
TipRanks · 12/02/2024 16:25
Xoma Royalty acquires Pulmokine for $20M
TipRanks · 12/02/2024 12:40
More
Webull provides a variety of real-time XOMA stock news. You can receive the latest news about XOMA Royalty Corporation through multiple platforms. This information may help you make smarter investment decisions.
About XOMA
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).